Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00061477
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2003-05-28
Brief Title:
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma A Phase II Clinical Trial
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine
1 The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs
2 Whether Pemetrexed plus Gemcitabine can help patients with mesothelioma live longer
3 Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear and for how long
4 To see if patients feel better while taking Pemetrexed plus Gemcitabine
1 The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs
2 Whether Pemetrexed plus Gemcitabine can help patients with mesothelioma live longer
3 Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear and for how long
4 To see if patients feel better while taking Pemetrexed plus Gemcitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-US-JMFZ | None | None | None |